✦ LIBER ✦

PUK17 Cost-Mimimization Analysis of Pazopanib Versus Sunitinib, Sorafenib and Bevacizumab+ Interferon á-2a for Patients With Metastatic Renal Cell Carcinoma

✍ Scribed by M. Sura; S. Goryaynov; M. Avxentyeva; V. Omelyanovsky

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness And Cost-Utility Anal

✍ Torres Toala, F.G.; Albuja Riofrio, M.F.; Mould, J.F.; Estévez, C. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN59 Cost-Effectiveness of Pazopanib Ve

✍ Pepe, C.; Paladini, L.; Sedlmayer, C.; Machado, M. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

PCN26 COST-EFFECTIVENESS AND COST-UTILIT

✍ Salinas-Escudero, G; Contreras-Hernandez, I; Mould-Quevedo, J 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

PCN40 COST ANALYSIS OF MANAGING ADVERSE

✍ CI Silva; I Monteiro; B Schwander 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

PCN70 COST EFFECTIVENESS ANALYSIS OF SUN

✍ E Remák; H Vioix; R Sandin; U Harmenberg; A Ullén; P Sandström 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

PCN17 COST OF MANAGING SIDE EFFECTS OF F

✍ GH Mickisch; B Escudier; M Gore; G Procopio; S Walzer; MJ Nuijten 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB